What question did this study set out to answer?

This study aims to evaluate the efficacy and safety of belumosudil for patients with refractory chronic GvHD.

December 8, 2025BloodOpen Access

Efficacy and safety of the ROCK2-inhibitor belumosudil for chronic gvhd treatment: Multicenter retrospective analysis of a large german-austrian cohort of the belumosudil managed-access program.

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis reveals efficacy of belumosudil for refractory chronic GvHD with notable adverse events.

This study aims to evaluate the efficacy and safety of belumosudil for patients with refractory chronic GvHD.
Retrospective multicenter analysis including 113 patients from German and Austrian transplant centers.
Patients received belumosudil after two to five prior lines of treatment, including ruxolitinib if not intolerant.
Outcomes assessed using NIH-consensus criteria and adverse events recorded according to CTCAE.
A total of 113 patients were analyzed, with 89.6% failure-free survival at three months.
At six months, 61% showed partial remission or better, while overall survival was 91.5% at one year.
Adverse events included infections in 20% of patients, categorized by CTCAE criteria.

Holtick et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark